The Lynx Group
Cholangiocarcinoma News

Phase 2 Study Assessing Tolerability, Efficacy, and Biomarkers for Durvalumab ± Tremelimumab and Gemcitabine/Cisplatin in Chemo-Naïve Advanced BTC

Web Exclusives — May 30, 2020

Immunotherapies have shown early promising efficacy in some patients with biliary tract cancer (BTC). The authors assessed durvalumab (D) (anti–PD-L1) ± tremelimumab (T) (anti–CTLA-4), and gemcitabine/cisplatin (GemCis) as first-line treatment in Korean patients with BTC. The research team also performed an extensive biomarker analysis.1

Patients were first enrolled in the biomarker cohort to receive 1 cycle of gemcitabine 1000 mg/m2 + cisplatin 25 mg/m2 on days 1 and 8, followed by GemCis + D 1120 mg and tremelimumab 75 mg, every 3 weeks until disease progression. Subsequent patients were allocated to GemCis + D (3-combo cohort) or GemCis + D+T (4-combo cohort) until disease progression. In all cohorts, tumor biopsies were obtained pretreatment, after 1 cycle, and at disease progression. Blood samples for circulating tumor DNA were obtained at every cycle. Tumor mutational burden was assessed on pretreatment tumor samples, and PD-L1 expression was assessed on pre- and post-treatment tumor biopsy samples. A total of 121 patients were enrolled. Median follow-up durations were 28.5 months, 11.3 months, and 11.9 months in the biomarker cohort, 3-combo cohort, and 4-combo cohort arms, respectively.

Objective response rate and median overall survival were improved in cohorts 3 and 4 compared with the biomarker cohort. The most common adverse events (any grade) were nausea (59.5%), neutropenia (54.5%), and pruritus (54.5%). Candidate biomarkers were identified that may be indicative of response to these therapies. The most common grade 3/4 events were neutropenia (50.4%), anemia (35.5%), and thrombocytopenia (16.5%). The addition of immunotherapy to chemotherapy was tolerable and showed very promising efficacy. The combination of D + Gem/Cis is being investigated in the global phase 3 TOPAZ-1 trial (NCT03875235). ClinicalTrials.gov number NCT03046862.

Reference

  1. Oh D-Y, et al. ASCO 2020. Abstract 4520.

Related Items

Benefits of Lenvatinib plus Pembrolizumab in Solid Tumors, Including Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
First results of the multicohort phase 2 LEAP-005 study suggest that lenvatinib plus pembrolizumab combination immunotherapy has promising antitumor activity in patients with biliary tract cancer.
NTRK Gene Fusions in Biliary Tract Cancers
2020 Year in Review: Cholangiocarcinoma
Molecular analyses of biliary tract cancers indicate that neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare, suggesting that it is not a major driver of BTC pathogenesis.
The Worldwide Incidence of Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
Assessment of global epidemiologic trends in incidence of biliary tract cancers (BTCs) showed higher BTC incidence in Asian versus Western countries as well as intraregional variations within countries, which is consistent with previous reports.
Capecitabine and Cisplatin as Second-Line Chemotherapy for Patients with Advanced Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
Retrospective analysis data suggest that second-line chemotherapy of capecitabine and cisplatin combination therapy was associated with modest efficacy in patients with advanced biliary tract cancer.
Combination Immunotherapy with Ipilimumab and Nivolumab Shows Activity in Patients with Advanced Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
Preliminary data suggest that dual blockade with ipilimumab and nivolumab might have antitumor activity in a subset of patients with microsatellite-stable biliary tract cancer.
Nivolumab with Chemotherapy or Ipilimumab: First-Line Therapy for Patients with Advanced Unresectable Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
Phase 2 study results suggest that the addition of nivolumab and ipilimumab to chemotherapy as first-line therapy did not provide additional PFS benefit compared to standard-of-care chemotherapy in patients with advanced biliary tract cancer.
Phase 2 Study of Nivolumab with Gemcitabine/Cisplatin or Ipilimumab as First-Line Therapy for Patients with Advanced Unresectable BTC (BilT-01)
Web Exclusives
The combinations of nivolumab with gemcitabine/cisplatin or nivolumab with ipilimumab were tested in patients with untreated advanced biliary tract cancer.
Combination Immunotherapy with Ipilimumab and Nivolumab in Patients with Advanced Biliary Tract Cancer
Web Exclusives
The response rate to the combination of ipilimumab and nivolumab in patients with advanced biliary tract cancer compared favorably to clinical trials investigating single-agent anti–PD-1 therapy.
Phase 2 Study of mFOLFOX versus mFOLFIRI in Locally Advanced or Metastatic BTC Refractory to First-Line Chemotherapy
Web Exclusives
This randomized phase 2 study showed that mFOLFIRI was not superior to mFOLFOX as second-line treatment of biliary tract cancer.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: